AstraZeneca Hopes To Differentiate Benralizumab On Efficacy, Dosing Convenience
This article was originally published in The Pink Sheet Daily
Executive Summary
Biologic for severe asthma meets primary endpoint in two pivotal studies, but greater detail will be needed to differentiate the drug from already-approved Nucala and Cinqair.
You may also be interested in...
On The Respiratory Horizon: A Wave Of Biologics For Asthma
Several antibody drugs are in late-stage development to treat severe asthma and could reach the market in the next two years. But competition for niche subsets of patients will be fierce, and tailoring the right medications to the right patients to justify the higher cost of treatment will require advances in biomarker development.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.